Clinical Trial Update: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents [Phase 2]

View source ↗

Summary

Phase 2 study comparing standard of care versus a triplet targeted immunotherapy combination in Fallopian tube mucinous adenocarcinoma and ovarian seromucinous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Endometrioid Adenocarcinoma
• Fallopian Tube High Grade Serous Adenocarcinoma
• Fallopian Tube Mucinous Adenocarcinoma
• Ovarian High Grade Serous Adenocarcinoma
• Ovarian Mucinous Adenocarcinoma
• Ovarian Seromucinous Carcinoma
• Platinum-refractory Fallopian Tube Carcinoma
• Platinum-refractory Ovarian Carcinoma

Drugs mentioned

• Triplet combination of targeted immunotherapeutic agents

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-18